In a separate study another team of researchers found an association between mutations in ARID1A and the development of ovarian clear cell and endometrioid carcinomas
In the study, we tested if PTEN loss/mutation leads to upregulation of NDRG1 expression during carcinogenesis of endometrioid carcinoma
Treatment modalities include total abdominal hysterectomy and bilateral salpingo-oopherectomy, as well as chemotherapy and radiotherapy, with regimens similar to those for endometrioid carcinoma
FIGO grade 3.
of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms.
Overlap of both morphologic and molecular features between high-grade endometrioid and high-grade serous carcinomas has led some pathologists to default most of the gland-forming or near-solid, cytologically high-grade ovarian carcinomas to the serous category, to the degree that "true" high-grade endometrioid carcinomas
are considered by some to be rare.
44,46) Basically, if both tumors are low-grade endometrioid and involved sites are limited to uterine corpus and ovary, the prognosis is favorable, while type 2 (serous and clear cell) carcinomas, high-grade endometrioid carcinomas
, and involvement of other stage III sites in addition to ovary portend a grave prognosis.
The p53 expression in both glands and stroma showed a significant correlation with the degree of differentiation of endometrioid carcinoma
One endometrial polyp, obtained from a case of cryopreserved endometrioid carcinoma
, and 9 frozen archived endometrioid endometrial carcinomas were also analyzed by immunohistochemistry in order to examine expression of CD117 in malignant endometria, as well as to identify suitable cases for CD117 immunoprecipitation and Western blot analysis (selection criteria and blotting methodology are described below).
found that 76% of the tumors were low-grade (grade 1 or 2) endometrioid carcinomas
Differential expression of WT1 and p53 in serous and endometrioid carcinomas
of the endometrium.
In a combined analysis of immunohistochemical staining of grade 3 endometrioid endometrial carcinomas for MLH1, MSH2, p16, cyclin D1, ERBB2, WT1, and p53,37% of cases had molecular profiles that resembled endometrioid carcinomas
, and the other 63% of cases resembled serous carcinomas at the molecular level (57).
The histologic types included 36 serous carcinomas, 10 mucinous carcinomas, 11 endometrioid carcinomas
, 5 clear cell neoplasms, 5 undifferentiated carcinomas, 1 mixed tumor (serous undifferentiated), 6 nonepithelial tumors, and 11 tumors of borderline malignancy (5 mucinous, 5 serous, and 1 endometrioid).